Additionally, IL17A has been shown to promote metastasis in a pre-clinical model using K-ras-driven NSCLC cell line, a process that was shown to be driven through IL-6 signaling (60, 61). This evidence concerns the gene KRAS and non-small cell lung carcinoma.